Asset profile
LV232
Small molecule
Evidence outlook · lead readout
NCT06476509 · Major Depressive Disorder
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06476509: This trial was not randomized and had no blinding, and its purpose was to measure a brain-receptor occupancy reading with a PET scan rather than any change in mood or depression symptoms. With only 20 participants and no results posted, it offers only a narrow, early look at how the drug behaves in the brain, not evidence of a therapeutic effect.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
September 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.